Introduction
Inorganic phosphate (Pi) is essential for various cellular metabolism and skeletal mineralization. It is an essential part of nucleic acids and the cell membrane, serves as an important mediator of intracellular signaling, and regulates protein activity. About 600 g (500-700 g) of phosphorus is present in normal adults, of which 80% to 85% is present in bone mineral. In serum, most of the phosphorus is present as Pi in normal concentration of 0.75 to 1.45 mmol/L (2.5 to 4.5 mg/dL). More than 85% of Pi in serum is present as the free ion and less than 15% is protein-bound. Free 2-and NaHPO4 -predominantly account for~75% of the total phosphorus and free H2PO4 -accounts for~10%.
Major determinants of serum phosphorus concentration are dietary intake and gastrointestinal absorption of phosphorus, mainly via upper small intestine, urinary excretion of phosphorus, and shifts between the intracellular and extracellular spaces. Abnormalities in any of these steps can result either in hypophosphatemia or hyperphosphatemia 1, 2) . Lower than age-appropriate levels of serum phosphorus are associated with severe skeletal defects and growth failure, unless appropriately treated 3, 4) . The kidney is a major . 1, 6) . 
Phosphate transport molecules
Three types of Na + /Pi cotransporters (types I-III; solute carrier series SLC17, SLC34, and SLC20, respectively, in the human gene nomenclature database) have been identiied in the proximal tubules of the rat kidney 3, 4) . The type I Na + /Pi transporter is expressed in the liver and kidney 3) .
Its expression and activity are not regulated by the dietary phosphate or PTH status. Recent studies suggest that expression of the type I gene (Npt1) is transcriptionally regulated 7) and that Npt1 may function as a modulator of intrinsic cellular Pi transport rather than a Na + /Pi cotransporter 8) , but its role in the regulation of Pi homeostasis remains unclear 9) . By contrast, the type II Na + /Pi cotransporter (NPT2, NaPi2, NaPi3) is the major molecule in the renal proximal tubule and is regulated by Pi, parathyroid hormone, fibroblast growth factor 23 (FGF23) (except Type IIb), and by 1,25-dihydroxyvitamin D
(1,25(OH)2D) and it is responsible for most of Pi reabsorption in the kidney and intestine 5, 10, 11) . . Type IIc Na + /Pi cotransporter is identified as the growth-related Pi transporter expressed in the kidney 14) . Recent studies have led to the identification of homozygous or compound heterozygous mutations in SLC34A3, the gene encoding the Na + /Pi cotransporter NPT2c, in patients affected by HHRH (hereditary hypophosphatemic rickets with hypercalciuria) [15] [16] [17] . These findings indicate that NPT2c has a more important role in phosphate homeostasis than previously thought. Regulation of the type IIc Na . These proteins have been known as receptors for gibbon ape leukemia virus (Glvr) and murine amphotropic retrovirus (Ram-1) 19) . In contrast to type I and type II Na are ubiquitously expressed in most species and particularly abundant in the kidney, liver, lung, muscle, heart, and brain 19) . Furthermore, PiT1 and PiT2 function as Na + -dependent Pi transporters 19) . PiT is involved in the regulation of bone mineralization. In the kidney, type III Na . Thus, the type III transporters are likely to serve as a housekeeping function and act as important me-diators of cell-mediated matrix mineralization. . PTH, vitamin D, and dietary Pi intake have long been known as major regulators of serum phosphorus 5) . In the proximal tubules, PTH inhibits reabsorption of phosphorus via effects on NPT2a and NPT2c 11, 20, 21) . .
physiological regulation
Novel factors regulating Pi homeostasis . PHEX also plays a major role in renal phosphate handling but is not expressed in the kidney, suggesting the secondary involvement of a circulating systemic factor. Recent studies confirm that, under normal conditions, PHEX gene expression degrades and inactivates hormone-like substances. The "circulating factor" called phosphatonins promotes phosphate excretion and impairs bone mineralization. Therefore PHEX may also play a key role in phosphate homeostasis and mineralization 23) . PHEX gene mutations lead to underexpression of the Na + /Pi cotransporter in the kidney 24) . In patients with X-linked hypophosphatemia (XLH), inactivating mutations of PHEX probably result in a failure to inactivate the phosphatonins.
FGF23
FGF23 is a recently identified member of the fibroblast growth factor family. FGF23 is thought to be one of the key molecules involved in the regulation of phosphate homeostasis and skeletogenesis 25) . FGF23 is required for normal phosphate balance and acts by suppressing both the reabsorption of phosphate in the renal tubule and the biosynthesis of 1,25(OH)2D. In human studies, and particularly in rodents, changes in serum phosphorus levels have been found to regulate serum FGF23 [26] [27] [28] . . FGF23 expression in bone is normally suppressed by PHEX. So deficiency of PHEX results in increased serum FGF23 and renal phosphate wasting (as seen in patients with XLH). FGF23 also inhibits PTH synthesis in the parathyroid 32) . Recent studies suggest that FGF23 acts via known FGF receptor (FGFR). In cultured opossum kidney cells, a cell line with a proximal tubular phenotype, FGF23 binds to the FGFR type 3c 33) . Klotho, a membrane bound protein with -glucuronidase activity, is also required β as a co-receptor for FGF23 action. Klotho can bind FGF23, and its co-expression in cells converts FGFR1(IIIc) into a functional FGF23 receptor 34) . The Klotho null animals show markedly elevated serum levels of FGF23 34) . Fig. 1 
Other phosphaturic factors
A number of recent studies suggest that secreted friz- mutations in the sodium hydrogen exchanger -regulatory factor 1 (NHERF1) 38) . In the NHERF1 protein, two structural domains, named PDZ1 and PDZ2, were reported to be interacting proteins. PDZ1-domain protein interacts with the C-terminal tail of NPT2a 38) and also NPT2c 40) and plays an important role in renal Pi reabsorption by PTNa interacts with the renal receptor and markedly decreases NPT2 mRNA and protein content (Fig. 3) 45)
. Fig. 2 . Phosphate Transport inhibition by parathyroid hormone (PTH) through sodium hydrogen exchanger -regulatory factor 1 (NHERF1) phosphorylation 38) . PKA, protein kinase A; PKC, protein kinase C; NPT2, type II Na + /Pi cotransporter; PDZK1, PDZ domain containing 1 protein; PTH1R, PTH type 1 receptor.
Tumor-induced osteomalacia
Severe hypophosphatemia with osteomalacia and, if growth plates are still open, rickets, can occur as an acquired disorder in association with a tumor. Tumor extracts inhibit phosphate transport in renal epithelial cells and reduced both phosphate and calcitriol production in experimental animals. The tumor extract affects only phosphate transport, in contrast to PTH, it has no effect on calcium metabolism. Three potential phosphaturic hormones have been concerned in Tumor-induced osteomalacia (TIO): FGF23, MEPE, and SFRP4 35, 36, 46, 47) . Serum FGF23 was elevated in patients with TIO and fell after surgery for removal. Clinical features are similar to XLH. Plasma calcitriol level is reduced, even though elevated levels are to be expected in the presence of hypophosphatemia. Thus, the underlying tubular defect that impairs phosphate reabsorption also appears to affect calcitriol synthesis. TIO tumor cells produce PTNa in excess. The increased PTN production, through a feedback mechanism, enhances PHEX production. However, the overproduction of PTNa exceeds the capability of PHEX to degrade sufficient amounts of the product to PTNi. Hence, in spite of enhanced PHEX, with an overabundance of PTNa, interaction with the receptor decreases the NPT2 mRNA and protein production (Fig. 4) 45)
.
Type IIa Na +

/Pi cotransporter deficiency
The homozygous ablation of Npt2a gene in mice Fig. 3 . Pathophysiologic basis for X-linked hypophosphatemia (XLH) 45) . PHEX, Phosphate regulating gene with homologies to Endopeptidase, on the X chromosome; PTN, phosphatonin, PTNa, active PTN; PTNi, inactive phosphatonin; NPT2, type II Na+/Pi cotransporter. 45) . PHEX, Phosphate regulating gene with homologies to Endopeptidase, on the X chromosome; PTN, phosphatonin, PTNa, active PTN; PTNi, inactive phosphatonin; NPT2, type II Na+/Pi cotransporter.
(Npt2a / − − ) results from increased urinary phosphate excretion leading to hypophosphatemia 12) . Npt2c protein abundance is significantly increased in Npt2a / − − mice 48) , although up-regulation of Npt2c is not sufficient to compensate for loss of Npt2a function. Due to the hypophosphatemia, Npt2a-ablated mice show an appropriate elevation in the serum levels of 1,25(OH)2D leading to hypercalcemia, hypercalciuria, and decreased serum PTH levels.
A study reported by Prie D et al. 49) showed that heterozygous mutations in the NPT2a gene may be responsible for hypophosphatemia and urinary phosphate loss in patients with urolithiasis or bone demineralization.
NHERF1 mutations
Recent studies from animal models suggest that NHERF1 controls renal phosphate transport. The study reported by Karim et al. 38) identifies NHERF1 mutations as a cause of renal phosphate loss that may increase the risk of renal stone formation or bone demineralization together with normal serum PTH concentrations. This study was carried out for the NHERF1 gene in 158 patients, 94 of whom had either nephrolithiasis or bone demineralization and identified three distinct mutations in seven patients with a low value of tubular maximal reabsorption of phosphate corrected for glomerular filtration rate (TmP/GFR).
This study also showed increased PTH-induced cyclic adenosine monophosphate (cAMP) generation and then the inhibition of phosphate transport. Urinary cAMP excretion was significantly higher in the patients with NHERF1 mutations than patients without NHERF1 mutations 38) . PTH induced a significant decrease of phosphate uptake in all cell groups 38) . However, both PTH-induced cAMP generation and PTH-induced inhibition of phosphate uptake were increased in mutant NHERF1 complementary DNA (cDNA) as compared with human wild-type NHERF1 cDNA 38) .
Autosomal dominant hypophosphatemic rickets/osteomalacia
Autosomal dominant hypophophatemic rickets (ADHR)
is a rare isolated renal phosphate wasting disease with rickets or osteomalacia that is transmitted as an autosomal dominant trait. ADHR results from heterozygous mutations in FGF23 gene on chromosome 12p13 50) . [15] [16] [17] .
Hypophosphatemic rickets and/or osteomalacia is the clinical manifestation in most patients. Nephrolithiasis associated with hypercalciuria frequently occurs, probably due to elevated serum 1,25(OH)2D that leads to increased intestinal absorption of calcium and phosphorus. Serum FGF23 is low to low-normal in HHRH 15) . Long-term phosphate supplementation is the only therapy in HHRH. 
Conclusion
